Market Research Blog – Page 14902 – New Product Development

Systemic Mastocytosis Treatment Market Size (Value & Volume), Future Trends, Opportunities and Sales Channels, Forecast 2028

Systemic mastocytosis is rare disease which affects very few people and it causes due to C-kit mutation which leads to higher number of mast cell production in the body resulting in accumulation of excessive mast cells in the internal body organs such as spleen, liver, bone marrow and small intestine etc. Recently in 2016, World Health Organization (WHO) updated the prognosis, diagnosis and systemic mastocytosis treatment guidelines for the disease which in turn helped to bring uniformity in the approach by healthcare professionals. The manufacturers in the systemic mastocytosis treatment market are focusing on evaluating possible treatment options to cure the disease by investing heavily in the research & development. Various leading manufacturers are focusing on gaining FDA approval to respective drugs for the systemic mastocytosis treatment to enhance their revenue generation.

Systemic Mastocytosis Treatment Market: Drivers and Restraints

Increasing awareness about the systemic mastocytosis treatment as well as symptoms of the disease due to extended effort by non-profit organizations, governmental associations and through other platforms expected to drive the growth of the systemic mastocytosis treatment market. Updation by WHO in diagnosis, prognosis and treatment approach helped gain traction, driving the growth of systemic mastocytosis treatment market. Increasing approvals and launches of drugs for the systemic mastocytosis treatment expected to drive the growth of the market. E.g. In Feb. 2019, Blueprint Medicines Corporation received approval for the start of clinical phase III trial of avapritinib for systemic mastocytosis treatment which in turn expected to fuel the growth of the systemic mastocytosis treatment market. Increasing spending on research & development by various pharmaceutical companies to develop novel systemic mastocytosis treatment expected to further fuel the growth of market. Increasing early diagnosis rate subsequently followed by increasing treatment seeking rate further expected to drive the growth of the systemic mastocytosis treatment market. Whereas, varying person to person prognosis of the systemic mastocytosis treatment approach may hamper the potential growth of the systemic mastocytosis treatment market.

To remain ‘ahead’ of your competitors, request for a sample @ https://www.futuremarketinsights.com/reports/sample/REP-GB-9183

Systemic Mastocytosis Treatment Market: Overview

The global systemic mastocytosis treatment market is expected to experience significant growth due to increasing novel treatment options. By drug class, systemic mastocytosis treatment market is expected to be dominated by the mast cell stabilizers due to superior efficacy. By indication, systemic mastocytosis treatment market is expected to be dominated by indolent systemic mastocytosis (ISM) due to higher prevalence. By route o administration, systemic mastocytosis treatment market is expected to be dominated by injectables. By distribution channel, systemic mastocytosis treatment market is expected to be dominated by the retail pharmacies due to higher patient footfall.

Systemic Mastocytosis Treatment Market: Regional Outlook

The global systemic mastocytosis treatment market is expected to be dominated by the North America due to comparatively higher prevalence of the disease. Europe systemic mastocytosis treatment market is expected to be second most lucrative market due to higher treatment seeking rate. Latin America expected to show gradual growth in the systemic mastocytosis treatment market due to steadily increasing diagnosis. Asia-Pacific is emerging systemic mastocytosis treatment market due to increasing diagnosis subsequently followed by treatment. Middle East & Africa is the least lucrative systemic mastocytosis treatment market due to least diagnostic rate and lower awareness about the symptoms.

Systemic Mastocytosis Treatment Market: Key Players

The key market players operating in the systemic mastocytosis treatment market are: Bausch Health Companies Inc., Pfizer Inc., Merck & Co. Inc., Mylan NV, Teva Pharmaceutical Industries Ltd., Sanofi S.A., Johnson & Johnson, Novartis AG, Bayer AG, Mallinckrodt Pharmaceuticals, EPI Health, LLC, and Kaleo Inc.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to market segments such as geographies, application, and industry.

For critical insights, request for PDF Brochure – https://www.futuremarketinsights.com/reports/brochure/rep-gb-9183

Why Future Market Insights?

• Comprehensive analysis on evolving purchase pattern across different geographies
• Detailed insights of market segments and sub-segments for historical as well as forecast period
• A competitive analysis of prominent players and emerging players in the keyword market
• Detailed information about the product innovation, mergers and acquisitions lined up in upcoming years

Ground breaking research and market player-centric solutions for the upcoming decade according to the present market scenario

About FMI:

Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, the global financial capital, and has delivery centers in the U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Contact Us:

Mr. Debashish Roy
Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
MARKET ACCESS DMCC Initiative
For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com
Website: https://www.futuremarketinsights.com

Railcar Unloader Market Trends, Strong Application Scope, Key Players, Growth Overview and Forecast by 2028

Unloading bulk material from rail is often a difficult and dirty job; it is often labor-intensive, slow, messy, noisy and unsafe. For that purpose, railcar unloader machines are used to unload materials such as cement, coal, metal, oil, ash and others from rail cars. Railways are the cheapest and safest mode of transferring material from one place to another. Over the years, the rail car industry has grown tremendously as the shipments of crude oil and commodities have increased by 100% and the same growth is expected in the near future.

In addition, emerging rail regions, such as Latin America or Africa/Middle East, contribute to market growth through the continued development of rail systems and infrastructure.
Mega trends such as increasing safety & security concerns, globalization, urbanization or sustainability have a positive effect on the demand for rail parts & solutions. Additionally, the industry is also transformed by significant investments in rail infrastructure, rail services and control, the rail supply market has grown significantly. Therefore, railcar unloaders will play a significant role in unloading material from railcars.

To remain ‘ahead’ of your competitors, request for a sample @ https://www.futuremarketinsights.com/reports/sample/REP-GB-9174

Railcar Unloader Market: Driver

Globally, the growing need for transporting commodities in a more cost-effective manner for various industries is projected to fuel the demand for railcars. In addition, an increase in the number of various construction projects is anticipated to impact the growth of the global market significantly. As these unloaders are also used at construction sites for the unloading of bulk materials from railcars, these factors are expected to eventually upsurge the demand for railcar loaders during the forecast period.

Railcar Unloader Market: Restraint

Factors such as railcar derailments, strict government regulations and growing oil pipeline infrastructure are expected to hamper the demand for railcars and, in turn, hinder the growth of the railcar unloader market. In addition, limitations associated with the lack of availability of rail tank cars may also affect the demand for railcar unloaders during the forecast period.

Railcar Unloader Market: Trend

Manufacturers are focusing on innovation in product technology to sustain their share in the railcar loader market. For instance, nowadays, unloaders have a working noise level of less than 70 dBA and are available from multi-positioned minor units to single-positioned larger units that are designed to unload a unitrain in four to five hours. This is a trending opportunity for railcar unloader manufacturers.

Railcar Unloader Market: Market Participants

Loading platform canopies are often provided by loading platform manufacturers and account for most of the market share globally. Examples of some of the market participants/vendors identified in the railcar unloader market around the globe are:

Kinergy Corporation
Jamieson Equipment Co.
Process Control Corporation
The ACT Group
NPK
Airmatic Inc.
Scherzer GmbH

For critical insights, request for PDF Brochure – https://www.futuremarketinsights.com/reports/brochure/rep-gb-9174

Why Future Market Insights?

Ground breaking research and market player-centric solutions for the upcoming decade according to the present market scenario

About FMI:

Contact Us:

Surgical Site Infections Market Covid-19 Impact Analysis, Size, Share, Key Trends, Demand and Forecast till 2028

Surgical site infections are likely to occur post-surgery in the operated body part. Surgical site infections can also result into superficial infections that include just the skin. Apart from these superficial infections, surgical site infections can also be serious and at times, fatal involving organs, tissues under the skin, or the implanted material. According to the National Nosocomial Infections Surveillance system of the CDC (Centers of Disease Control and Prevention), approximately 27 million surgical procedures take place in the U.S., annually, that account for around 5% surgical site infections. As per the data provided by the NNIS, surgical site infections are reported to be the 3^rd most occurring nosocomial infections which are further linked with substantial morbidity, threatening life of a patient, increase in healthcare expenditure, and increase in the number of days in hospitals for patients. Surgical site infections are more likely to be reported 30 days post-surgery without an implant or within one year with the presence of implant. These infections are further classified as either organ/space or incisional infections. Incisional surgical site infections are segmented into deep or superficial infections.

Surgical Site Infections Market: Drivers and Restraints-

Rise in the incidence rates of surgical site infections, development of technologically advanced products, increase in number of surgeries performed globally, and growing geriatric population are expected to be the major factors contributing to the market growth for surgical site infections. Furthermore, improved government policies and strict regulatory scenario for surgical site infections is anticipated to fuel the market growth for surgical site infections during the forecast period. However, lack of awareness on infection control programs because of challenging priorities, limited resources, and other related barriers is expected to obstruct market growth for surgical site infections during the forecast period. Also, poor healthcare infrastructure in most developing region and low healthcare expenditure might hinder market growth for surgical site infections.

To remain ‘ahead’ of your competitors, request for a sample @ https://www.futuremarketinsights.com/reports/sample/REP-GB-9136

Surgical Site Infections Market: Overview

Hospitals are focusing on increasing the use of appropriate antimicrobial agents for surgical site preparation. Stringent policies regarding surgical site safety has enforced the hospitals to adopt adherence to aseptic techniques, both intra-operatively and pre-operatively. As per the Association for Professionals in Infection Control and Epidemiology, Inc., Methicillin-Resistant Staphylococcus Aureus accounted for around 50-70% of all healthcare-acquired staph infections. The CDC is highly focused on eliminating surgical site infections and further recommend that all the sites should be well-equipped and protected with sterile dressings within 24-48 hours of surgery. Superficial incisional surgical site infections are expected to contribute high revenue share in the surgical site infections market. Several collaborations and distribution agreements between manufacturers operating in the surgical site infections market are also taking place. For Instance, Johnson & Johnson partnered with the government of Maharashtra in 2018 for health interventions collaboration related to diabetes, infection prevention, menstrual hygiene, and obesity, and support healthcare providers.

Surgical Site Infections Market: Region-wise Outlook

The North America market for surgical site infections in expected to contribute the highest revenue share and is also, expected to dominate during the forecast period owing to the high number of surgeries performed in the region. Surgical site infections are considered to be the most common healthcare-related infection in acute care hospitals among inpatients in the U.S. The rise in need for the prevention of surgical site infections is expected to contribute to the market growth for surgical site infections in the region. As per the data provided by the ECDC (European Center for Disease Prevention and Control), 18,634 infection cases were reported for 2013-2014 in a total of 967,191 surgical procedures conducted in the region. The increase in healthcare expenditure is also expected to boost market growth for the region.

Surgical Site Infections Market: Key Market Participants

Some of the market participants in the Global Surgical Site Infections market identified across the value chain include: B. Braun Melsungen Ag, BD, Stryker Corporation, Medtronic, Surgical Site Infection Prevention LLC, bioMerieux SA, Johnson & Johnson, Steris Corporation, Belimed AG, and Kimberly-Clark Corporation.

For critical insights, request for PDF Brochure – https://www.futuremarketinsights.com/reports/brochure/rep-gb-9136

Why Future Market Insights?

Ground breaking research and market player-centric solutions for the upcoming decade according to the present market scenario

About FMI:

Contact Us:

Nephrology Stents and Catheters Market 2018: Global Industry Analysis, Size, Share, Growth, Trends And Forecast To 2028

Nephrology stents and catheters are one of the key products and treatment option in nephology for drainage of obstructed urine in patients. Blockage in of one or both the ureters leads to usage of nephrostomy stents and catheters. Nephrology stents and catheters are generally inserted under medication of local anaesthetic, which helps in temporal diversion of urine form blockade. Insertion of nephrostomy stents and catheters requires well-trained and qualified personnel. These nephrostomy procedures can also be a primary treatment option where antibiotics become ineffective. The most common usage of nephrology stents and catheters are in the patients suffering from cancer of reproductive organs. Other indications for usage of nephrology stents and catheters include UTI infections, benign prostate hyperplasia, urinary incontinence and others.

Nephrology Stents and Catheters: Market Dynamics

Over the years, increase incidence of kidney stone has been the primary market growth driver for nephrology stents and catheters market. Additionally, increasing incidence of various cancers in ovary, bladders and prostate etc. have increased the demand for usage of nephrology stents and catheters. Many reports have also reported that there is an increase in post-operative infection in kidney transplant patients and this has resulted in high demand for nephrostomy devices such as nephrology stents and catheters. However, stenting and catheterization challenges in percutaneous nephrostomy over the years have hindered the growth of global nephrology stents and catheters market.

To remain ‘ahead’ of your competitors, request for a sample @ https://www.futuremarketinsights.com/reports/sample/REP-GB-9133

Nephrology Stents and Catheters Market: Overview

The global market for nephrology stents and catheters is highly fragmented due to presence of local and global players. It is anticipated that major players will account for the largest share in the global nephrology stents and catheters market. Some of the new techniques and lunch of balloon dilation catheters having multilayer technology will help in driving the nephrology stents and catheters market. Amongst two category of nephrology products, catheters segment are anticipated to generate the maximum revenue in nephrology stents and catheters market.

Nephrology Stents and Catheters Market: Region-wise Outlook

Geographically, North America is anticipated to be leading region in terms of revenue in nephrology stents and catheters market followed by Europe. Increase incidence of ovarian, bladder and prostate cancer in both the regions are anticipated fuel the demand for usage of nephrology stents and catheters. In some of the growing economies of East Asia, South Asia and Latin America and South America, cancer awareness and their treatment will also drive nephrology stents and catheters market. However, lack of trained personnel in nephrology catheterization and stenting procedures in some regions of Africa and Middle East may adversely affect the market growth in the forecast period.

Nephrology Stents and Catheters Market: Key Players

The comprehensive market research report provides analysis of key manufacturers having significance presence in the market and their strategies which they follow to sustain the competitive environment of the nephrology stents and catheters market. The report also offers information about various research and developmental activities of these players that focus on to come up with innovative solutions. Some of the key and major players operating in global nephrology stents and catheters market include, Angiodynamics, Inc., Rocamed, Ameco Medical Industries, Boston Scientific Corporation, UROMED, Teleflex Incorporated, Cardinal Health Inc., C. R. Bard, Inc. Envaste Limited, Merit Medical Systems and Medi-globe Corporation . In addition presence of small and local manufacturers across the countries will account for competiveness in nephrology stents and catheters market.

For critical insights, request for PDF Brochure – https://www.futuremarketinsights.com/reports/brochure/rep-gb-9133

Why Future Market Insights?

Ground breaking research and market player-centric solutions for the upcoming decade according to the present market scenario

About FMI:

Contact Us:

Mast Cell Tumors Treatment Market Insights with Upcoming Trends Segmentation, Opportunities and Forecast to 2028

Mast cell tumor (Mastocytoma) is formed by aggregation of number of mast cells to form big cist like structure. It is a type of rare disease usually seen in infants aged from 0 to 3 months and rarely diagnosed in adults. Mast cells are associated with the histamine release and which causes allergic reactions when secreted in excess. Accumulation of extra mast cells generally appears in single to three lesions on body trunk or wrist. Activation of these extra mast cells results in excessive release of histamine and various different chemicals causing localized redness, swelling and itching. Increasing awareness about rare diseases resulting in improved diagnostic rate subsequently followed by increasing mast cell tumors treatment rate. Various manufacturers in the mast cell tumors treatment market are trying to develop novel treatment option by investing in mast cell tumors treatment research & development. Mast cell tumors (mastocytoma) is subtype of the cutaneous mastocytosis affecting approximately 10% to 30% of all cases. Although epidemiology of mast cell tumor is not clear but numerous controlled studies are being carried out to evaluate the actual epidemiology of the disease in different parts of the world. After the WHO updated the classification, diagnosis, and treatment approach, various countries implemented the same guidelines to improve uniformity in the diagnostic and treatment approach.

Mast Cell Tumors Treatment Market: Drivers and Restraints

Increasing data availability around disease expected to improve the treatment approach in turn driving the growth of the mast cell tumors treatment market. Increasing awareness about mast cell tumors treatment option through social media platforms, advocacy groups, various government and non-government organizations expected to improve treatment seeking rate, driving the growth of mast cell tumors treatment market. Improving diagnosis rate followed by increased mast cell tumors treatment seeking rate expected to fuel the growth of the market. Extended efforts by the manufacturers to develop novel mast cell tumors treatment due to various benefits offered by regulatory authorities under orphan drug status further expected to fuel the growth of the mast cell tumors treatment market. Whereas, patient to patient varying symptoms makes mast cell tumors treatment difficult, which may hamper the potential growth of the mast cell tumors treatment market.

To remain ‘ahead’ of your competitors, request for a sample @ https://www.futuremarketinsights.com/reports/sample/REP-GB-9131

Mast Cell Tumors Treatment Market: Overview

Mast cell tumors treatment market is expected to experience steady growth over the forecast period attributing to increasing diagnosis rate and mast cell tumors treatment seeking rate. By drug class, antihistamine is expected to be the most lucrative segment in the global mast cell tumors treatment market. By route of administration, oral is expected to be most lucrative segment in the mast cell tumors treatment market. By distribution channel, hospital pharmacies is expected to be highest revenue generating segment in the mast cell tumors treatment market. Various pharmaceutical manufacturers are planning to evaluate different molecules for mast cell tumors treatment e.g. In November 2018, GT Biopharma received FDA clearance for the human phase study of First-in-Class Tri-Specific Killer Engager (TriKE), GTB-3550.

Mast Cell Tumors Treatment Market: Regional Outlook

The global mast cell tumors treatment market is expected to be dominated by North America due to comparatively higher prevalence of the mast cell tumors in the region. Europe is expected to be second most lucrative mast cell tumors treatment market due to increasing treatment seeking rate. Asia-Pacific is emerging mast cell tumors treatment market attributing to increase in diagnosis rate as well as product availability. Latin America mast cell tumors treatment market is expected to experience gradual growth whereas MEA mast cell tumors treatment market expected to be least lucrative due to low prevalence as well as low diagnosis.

Mast Cell Tumors Treatment Market: Key Players

The key market players operating in the mast cell tumors treatment market are:, Pfizer Inc.,Bausch Health Companies Inc., Mylan NV, Merck & Co. Inc., Teva Pharmaceutical Industries Ltd., Johnson & Johnson, Sanofi S.A., Bayer AG, Novartis AG, EPI Health, LLC, and others.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to Mast Cell Tumors Treatment market segments such as geographies, application, and industry.

For critical insights, request for PDF Brochure – https://www.futuremarketinsights.com/reports/brochure/rep-gb-9131

Why Future Market Insights?

Ground breaking research and market player-centric solutions for the upcoming decade according to the present market scenario

About FMI:

Contact Us:

Bubble Tea Market 2022 | Scope of Current and Future Industry 2031

According to the latest Future Market Insights (FMI), the global bubble tea market will report 8.8% CAGR between 2021 and 2031. Consumers across the world know bubble tea as bubble milk tea, boba juice, boba tea, or pearl tea. Bubble tea is made with common tea ingredients plus chewy tapioca balls, earning it the nickname “pearl tea.”

Availability of bubble in a variety of flavors, including peach, plum, mango, passion fruit, coffee, chocolate, and strawberry, depending on the flavour of the tapioca balls has made it hugely popular globally.

Request a Sample of this Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-12310

The chewy tapioca balls don’t have a lot of calories in them. According to studies, a 1.1 ounce serving of uncooked pearls contains 68 calories, but when tapioca balls are soaked in sugar mixture, their calorie count rises, potentially slowing the market’s growth.

bubble tea market key regions and base ingredient mekko chart 2021

As a result, numerous tea makers are shifting their focus to healthier versions of bubble tea with reduced fat and calorie content. Many are even using taglines to promote their products, emphasizing the antioxidant and anti-inflammatory effects of their bubble tea.

It is frequently sold at a low price to introduce customers to several flavors and encourage them to establish a bubble tea habit over time. Many brands add fruits and jellies to their bubble tea to cater to the dynamic consumer preference.

Key Highlights

Global bubble tea market is estimated to reach US$ 2.3 Bn in 2021.
In terms of the base ingredient, black tea, which will represents over 36% of the market by 2031, will remain dominant through the forecast period.
On the basis of flavour, bubble tea market is segmented into original and flavored. In 2021, the flavoured bubble tea segment will represent 67.2% of the market.
East Asia holds dominance in the global bubble tea market. Within East Asia, China will represent the largest market share.
Within North America, the U.S. will hold dominance, accounting for a little over76% of bubble tea sold in the region.

“Bubble tea companies are attempting to strike the perfect balance between acquisition and retention, especially since small firms don’t have a lot of money to spend on marketing. Digital loyalty programs are used by brands because they can gather and utilize data at a minimal cost.” said a lead analyst at FMI.

Ask An Analyst @ https://www.futuremarketinsights.com/ask-the-analyst/rep-gb-12310

Social Media Influencing Choices of Customers, Especially Among Youth

Social media is full of advertisements, news, and other impactful visuals. Brands often use social media to target their consumers. Restaurants use social media to promote their drink specials and happy hours. Additionally, social media is where parties and get-togethers are organized. Because social media is such an integral part of people’s lives, it can also influence the way they drink.

It is unique platform where in that bubble tea brands can target consumers and create relationships with their audience. Users are often asked to “like” brands, to attend their events, and share photos of themselves using their products. In other words, social media is the perfect environment for bubble tea to be displayed, viewed, bought, and sold. Hence focus on social media penetration is expected to grow among market players.

Who is Winning?

Companies operating in the bubble tea market are focusing on expanding their footprint in developing markets. For instance:

In 2017, Chatime was launched in Mumbai, India by Alchemist Foods Ltd from Taiwan. The store catered to provide freshly brewed bubble tea while penetrating the local beverages market
Chatime Malay stated in January 2019 that it was planned to grow its presence aggressively into Singapore, the United States, India and Saudi Arabia as part of their five-year expansion strategy

Some of the leading companies offering bubble tea are Gong Cha, Kung Fu Tea, Lollicup USA, Tiger Sugar, Sharetea, Boba Guys, Tapioca Express, Cha Time, Tea Ren’s Tea Time, YiFang Bubble Tea, CoCo Fresh Tea & Juice, DaBoba, Happy Lemon, Quickly, Cojiitii, and othes.

Get Valuable Insights into Bubble Tea Market

Future Market Insights, in its new offering, provides an unbiased analysis of the bubble tea market presenting historical demand data (2016-2020) and forecast statistics for the period from 2021-2031. The study divulges compelling insights on the bubble tea market based on base ingredient (black tea, green tea, oolong tea, white tea, and others), flavour (original and flavored), sugar content (regular and reduced sugar/sugar free), format (ready-to-drink (rtd) and instant mixes), toppings (pearl, grass jelly, coconut jelly, red bean, and multiple/others), and by distribution channel (direct (B2B), indirect (B2C), and Online Retailing) across seven major regions.

Key Questions Answered in the Report

What is the bubble tea market size?
What is the most popular bubble tea flavor?
What are the key trends shaping the bubble tea market?
Who are the leading players in the bubble tea market?
How was post-COVID bubble tea market performance?
What is the North America bubble tea market outlook?
What is the Europe bubble tea market outlook?

Buy Complete Report @ https://www.futuremarketinsights.com/checkout/12310

Contact Us:

Future Market Insights
Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com
Website: https://www.futuremarketinsights.com

Air-dried Food Market 2022 | Current and Future Demand, Analysis, Growth and Forecast By 2030

The rising demand for healthy food that can be stored over a longer period of time has proven to be a boon for the air-dried food market. Future Market Insights (FMI) in a recent study has forecast the market to rise at an impressive pace, a trend which is expected to gather steam in response to increasing health consciousness among consumers.

Market surveys suggest, consumers are more willing than ever before to pay premium price for healthy food. Air drying food helps preserve its nutrients while extending the shelf-life without using any artificial additives. More generally speaking, it is a process of evaporation that helps rid moisture from food thus eliminating the risk of contamination due to bacteria, mold, or yeast.

Request a Sample of this Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-12304

Foray of novel and advanced packaging technologies is expected to facilitate expansion of the market. Some of the leading manufacturers are adopting these advanced techniques to air dry food and make them available at a commercial scale. Packaging also helps improving the longevity of the food item.

airdried food market characteristics and attributes with regional relevence

Dehydrating food is practiced in both household and commercial levels. Market today has several machines, both indigenous and high-end, available for dehydrating smaller quantities of food for home consumption. Commercially, some of the leading food producers use air drying techniques to manufacture ready-to-eat and ready-for-consumption packaged foods.

This is another chief driver of the market. According to FMI, despite their hectic lifestyle, consumers are looking for convenient food that have high nutritive value. Furthermore, awareness pertaining to health and wellness has made them wary about preservatives used in frozen or packaged food. This invariably creates a market, ready to accept the air drying technology that offers better convenience without compromising on the overall quality of food.

FMI in its recent report studies various factors impacting the trajectory of the air-dried food market. It covers factors driving growth and those restraining it. The report also uncovers hidden opportunities for market players. It offers key insights into the market. Some of these are:

Rising commercial application will give tailwinds to the growth witnessed in the air-dried food market
Coffee beans are expected to comprise leading market share in terms of products
Europe is expected to dominate the global market, however, demand from Asia Pacific is poised to surge considerably over the coming years
Air-dried fruits have become a highly popular and high-energy snacking option among consumers

Ask An Analyst @ https://www.futuremarketinsights.com/ask-the-analyst/rep-gb-12304

Who is winning?

The global air-dried food market is characterized by the presence of numerous market players, which has rendered it fragmented. Therefore the market is witnessing frequent product launches besides strategic collaborations as companies aim at gaining competitive advantage. Evidently, they are also under pressure to maintain competitive pricing.

FMI profiles some of the leading companies operating in the global air-dried food market. These include DMH Ingredients, Inc., Dehydrates Inc., Berrifine A, La Frubense, BCFoods, Inc., Saraf Foods Pvt. Ltd., B-B Products (Australia) Pty Ltd., Nestle S.A., FREEZE-DRY FOODS, HOWENIA ENTERPRISE CO., LTD.

Air-dried Food Market: The Way Forward

Impressive growth is on card for the air dried food market, especially as consumers look for healthy food items with extended shelf life. Sales uptick is likely especially on account of the ongoing pandemic crisis.

The unprecedented COVID-19 outbreak has triggered consumer behavior of stockpiling on essential goods. This will have a positive impact on the air-dried food market especially since economies are on the verge of relaxing stringent lockdown measures to resume normal course of living.

The air dried food market will record growth, albeit at a stunted rate, which it is expected to recover as soon as the pandemic passes. In the last couple of years, the market has registered impressive growth thanks to improved access to technologies. Advent of ho-tech packaging and storage facilities also is expected to bode well for the market.

Get Valuable Insights into Air-dried Food Market

Future Market Insights, in its new report, presents an unbiased analysis of the global air-dried food market, covering historical demand data and forecast figures for the period between 2020 and 2030. The study divulges compelling insights into growth witnessed in the market. On the basis of form, the market is segmented into powder & granule, chunks & pieces, and flakes. In terms of end user, the market can be bifurcated between commercial and household sectors. Regionally, the market covers North America, Latin America, Europe, East Asia, South Asia and ASEAN, and the Middle East and Africa

Key Segment

Form

Powder & Granule
Chunks & Pieces
Flakes

End User

Household
Commercial

Region

North America
Latin America
Europe
East Asia
South Asia and AEAN
MEA

Buy Complete Report @ https://www.futuremarketinsights.com/checkout/12304

Hydroxyapatite Market 2022 Expectations & Growth Trends Highlighted Until 2030

As per a new market research report on hydroxyapatite published by Future Market Insights (FMI), the market is anticipated to reach a value over US$ 700 Mn by 2030 expanding at a CAGR of 8.7%.

Calcium phosphate, most commonly known as hydroxyapatite, is used as a bio active material, which interacts with tissues and also aids bone growth. It accounts for a relatively smaller share in the current scenario; however, it is expected to expand significantly over the forecast period. It is mostly applied as coatings over the conventionally-used titanium or stainless steel implants and are projected to play an important role in 3-D printing over the coming years. From medical research it has been found that the natural human bone comprises of 70% hydroxyapatite.

Request a Sample of this Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-12308

“In recent years, with the advent of 3D printing and use of biomaterials for prosthetics and implants, hydroxyapatite has continued to gain prominence in its use as a biomaterial. Moreover, with increased spending on healthcare devices and treatment, the market participants will benefit from adding a good value proposition” says the FMI analyst.

hydroxyapatite market regional price benchmark by grade

Key Takeaways of Hydroxyapatite Study

In terms of application, orthopedic implants are projected to hold a significant share in the global hydroxyapatite market owing to an increase in the number of knee, hip and joint replacement cases due to several factors such as the increasing aging population, accident and physical trauma, etc.
China and North America are expected to be the most promising regions in terms of product sales. Collectively, both regions are estimated to hold over half of the market share, in terms of value, during the forecast period
The global market for hydroxyapatite is fairly competitive, with consolidation primarily between the top 3 manufacturers
Key players in the market are focusing on product development as well as mergers and acquisitions to strengthen their business footprint in domestic and overseas market. Pre-emptive strategy has proven to be a key differentiator

In spite of the COVID-19 pandemic and the resultant lockdown on manufacturing, the perceived growth trend will continue to be unhindered. Though, in the initial months of 2020, the immediate lockdown will affect the production, supply and sales process, yet from the consistent demand from critical medical cases and required prosthetics, the demand of hydroxyapatite as the principal material would be sustained in the successive years. The global hydroxyapatite market is expected to witness a rebound during the first and second quarters of 2021.

Ask An Analyst @ https://www.futuremarketinsights.com/ask-the-analyst/rep-gb-12308

Hydroxyapatite Market: Region-wise Analysis

North America is estimated close in at 35% of the hydroxyapatite market value share, accounting for a prominent weightage during the forecast period. Asia Pacific is another prominent region whose growth rate is expected to leapfrog over other regions in the forecast period.

China and South East Asia are estimated to hold a prominent market share in terms of consumption of Hydroxyapatite.

Demand from North America and Europe is largely attributable to treatment of geriatric population, prosthetic implants for professional purposes, whereas, the demand from Asia Pacific and other countries are due to surging accident and trauma related cases and commercial development of the product.

It can also be reasoned that developed countries have been the early adopters whereas the developing countries are in the introductory stage of product adoption.

Hydroxyapatite Market: The Way Forward

Over the forecast period, Hydroxyapatite market is expected to witness a healthy growth of around 9% throughout the forecast period
Investments to explore and expand the application areas for hydroxyapatite are projected to boost demand for research grade
Orthopaedic implants are projected to witness growing demand for hydroxyapatite for coating applications whereas dental implants are projected to witness significant growth in the latter half of the forecast period
Having a strong product base and establishment of business footprint across regional markets have been the governing benchmark of the leading players of hydroxyapatite market.

Competitive Landscape:

Fluidinova, Bonesupport AB, Berkeley Advanced Biomaterials, Sigma Graft, Nano Interface Technology, SofSera, Plasma Biotal Ltd., and Premier Biomaterials are considered as some of the leading market players in the Hydroxyapatite market. The top 3-4 manufacturers hold around half of the global market share in which these players are adopting inorganic growth strategies for the business development. Key players such as Bone support AB and Berkeley Advanced Biomaterials are focused on collaboration and acquisition to expand their presence in the global market.

Hydroxyapatite Market Key Segment

By Grade

Medical Grade
Cosmetic Grade
Research Grade

By Application

Dental
Orthopedic
Biochemical research
Others

By Region

North America
Latin America
Western Europe
Eastern Europe
China
India
Japan
SEAP
Middle East & Africa

Buy Complete Report @ https://www.futuremarketinsights.com/checkout/12308

Contact Us:

Mucopolysaccharidosis (MPS) Treatment Market is projected to grow at a robust CAGR of 5.9% between 2022 and 2029

A market study presented by FMI ‘ Mucopolysaccharidosis Treatment Market: Global Industry Analysis 2014-2021 and Opportunity Assessment 2022-2029,’ explains the significant factors influencing the current market structure.

According to research, the mucopolysaccharidosis treatment is still emerging, and different geographies have implemented standard treatment options for the condition. However, there is no universally accepted treatment pattern for mucopolysaccharidosis. Mucopolysaccharidosis falls under rare diseases, which is a complex, diverse, constantly evolving field, and there is a significant shortage of medical and scientific data related to it. Mucopolysaccharidosis treatment and diagnosis involves complex managing requirements, which include long-term care, rehabilitation support, and a continuous treatment plan.

Request Sample Copy of Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-5880

Research Activities Uplift Stem Cell Therapy Application in MPS Treatment

In the present scenario, the drugs that are considered for mucopolysaccharidosis treatment, such as aldurazyme, naglazyme, vimizim, elaprase, mepsevii and hunterase, are the only regulated and recommended drugs present in the market. These drugs fall under enzyme replacement therapies, however, with present research initiatives for stem cell therapies, the latter is considered a prominent mucopolysaccharidosis treatment. Clinical research shows that stem cell transplantation covers a large area that is not covered with the more frequently recommended practice of enzyme replacement therapies, which changes the current market structure for mucopolysaccharidosis treatment, prioritising the latter.

Stem cell therapy is a therapeutic option for mucopolysaccharidosis patients suffering from a severe phenotype, as research shows the method can preserve neurocognition or can even help break the progressive neurodegeneration. The method is provided with strict selection criteria, which is followed by maintained regulations. Research shows that stem cell therapy as a treatment option is gaining popularity among healthcare professionals for mucopolysaccharidosis treatment, which can be attributed to the relation of its better reach towards a normal health condition for the patient.

Request a Complete TOC of this Report with figures: https://www.futuremarketinsights.com/toc/rep-gb-5880

Enzyme Replacement Therapy Remains Lucrative for Market Investors

As per further assessments of the mucopolysaccharidosis treatment market, it has been difficult to collect epidemiological data pertaining to rare diseases, especially mucopolysaccharidosis treatment, which is likely to impede the actual estimation of the economic burden associated with the condition. The cost estimation for each mucopolysaccharidosis treatment type is affecting and, in turn, creating a more vulnerable situation for the businesses and disrupting research & development activities for each company.

Enzyme replacement therapy is the most attractive segment for investors, however, the unavailability of reimbursement plans and precise treatment plans is encouraging most patient in developing regions to opt for symptomatic treatments instead of enzyme replacement therapy, which is still considered to be the standard mucopolysaccharidosis treatment.

Key Players Focus on Clinical Research of Treatment Models

The report segments the mucopolysaccharidosis treatment market into seven regions to elaborate on the regional trends pertaining to the treatment plan. Major players are focusing on increasing their market share in the Asia Pacific market through strategic collaborations with regional research institutes. There is a lack of awareness about rare diseases among the general public as well as in medical healthcare facilities in several emerging economies. According to a survey and industry report, it takes patients in the US an average of 7.6 years and patients in the UK an average of 5.6 years to actually receive a proper diagnosis. Moreover, it involves a team of healthcare professionals to actually get the right mucopolysaccharidosis treatment and diagnosis pattern for reported cases.

Manufacturers are in the process of introducing a considerable number of mucopolysaccharidosis treatment options, which are currently under clinical trials. An estimated 160 and above clinical trials are being performed for mucopolysaccharidosis treatment. Thus, ensuring that the manufacturers take this mucopolysaccharidosis treatment market to be lucrative and potential rich in terms of revenue. Medical research institutes play an important role in this particular market. They are expected to be the bridge between treatment plans and economical solutions for manufacturers, thus leaving an explicable and lucrative model for mucopolysaccharidosis treatment.

Get Customization in the Report, Enquire Now @ https://www.futuremarketinsights.com/customization-available/rep-gb-5880

The mucopolysaccharidosis treatment market includes companies such as BioMarin Takeda Pharmaceutical Company Limited, Sanofi S.A., and Ultragenyx Pharmaceutical Inc. BioMarin accounts for a significant value share in the present mucopolysaccharidosis treatment market. The currently existing promising drug types are expected to face competition from emerging candidates. In addition the mucopolysaccharidosis treatment products of other companies, such as Sangamo Therapeutics, Inc., REGENXBIO Inc., Sarepta Therapeutics, Abeona Therapeutics, Inc., and others, are also in the pipeline.

For a broader lookout of actionable insights on the global market for MPS treatment, write to the analyst at press@futuremarketinsights.com

RFID in Pharmaceuticals Market Key Players, Applications, Outlook, SWOT Analysis And Forecasts By 2028

Future Market Insights (FMI), in its new study, finds that the radio-frequency identification (RFID) in pharmaceuticals market was valued at over US$ 950 Mn in 2018, and is estimated to register a Y-o-Y growth at approximately 10% in 2019. Prospects remain remarkable for the RFID in pharmaceuticals industry, as efficiency-led actions of players continue to enhance the reliability and accuracy of their business operations.

The study finds that drug tracing system remains the most lucrative application of RFID in pharmaceutical industry, accounting for approximately 60% sales. Efforts of the FDA, in collaboration with pharmaceutical suppliers, to maintain a secure drug supply in the wake of rising counterfeit drugs prevalence, has encouraged the pharmaceutical industry to use RFID in combination with the electronic product code (EPC) for real-time tracking, tracing, and authentication of drugs.

According to the study, such preventative measures against infiltration of counterfeit drugs are likely to have a positive economic influence on legitimate companies, who are now focusing on the deployment of anti-counterfeiting solutions. Focus of the organized players in the pharmaceutical sector to safeguard authenticity of their products, while creating moats for counterfeiters, will continue to favour growth of the RFID in pharmaceutical market.

Request Sample Copy of Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-9508

Chipless RFID Sales Remain Over 2X of Chipped RFID

According to the study, chipless RFIDs continue to gain robust attractiveness in the pharmaceutical industry, as they eliminate the hardware-related challenges associated with their chipped counterparts. Additionally, RFIDs without ICs allude at significant cost reduction of the component, in turn complementing their development and demand on a wide scale. However, complexities linked with designing and development of chipless RFID, such as data transmission and encoding, continue to sustain the demand for the chipped RFID to a certain extent. The study finds that sales of chipless RFID will remain over 2X that of the chipped RFID in 2019.

The study expects RFID reader to remain the core component in the RFID in pharmaceutical market, with growing focus of pharma suppliers on effective identification of products prior to their collection, storage and shipping. Gains in the RFID in pharmaceutical market will remain complemented by sales of RFID tags, with revenues in 2018 accounting for over one-third market share.

Request a Complete TOC of this Report with figures: https://www.futuremarketinsights.com/toc/rep-gb-9508

Adoption Remains High among Drug Manufacturers

Application diversity of RFID in pharmaceutical industry has led its adoption among a wide range of end-users that range from drug manufacturers and drug wholesalers, to hospitals and clinics. The report estimates drug manufacturers to account for leading shares of the RFID in pharmaceutical market, who are constantly emphasizing on ensuring the authenticity of their products in the market. Adoption is expected to witness high-growth among drug wholesalers and hospitals and clinics, which collectively account for over two-fifth share of the market.

The study states that North America will remain the leading market for RFID in pharmaceutical, with Europe following the suit. Supremacy of developed economies in the RFID in pharmaceutical market is significantly attributed to stringent standards & regulations implemented for serialization, and relative greater prevalence of OTC and generic drugs in these regions. Additionally, focus of players in developed markets remains strong on brand protection, and preventing packaging-related product recalls, which in turn augurs well for growth of the RFID in pharmaceutical market.

Ask Us Your Questions About This Report: https://www.futuremarketinsights.com/ask-question/rep-gb-9508

This FMI study also offers a long-term forecast of the RFID in pharmaceutical market for the period between 2018 and 2028. The RFID in pharmaceutical market is envisaged to record a CAGR of over 8% through 2028. For more, write to press@futuremarketinsights.com